Why New Deal failed to sell cheap medicine 
 
 
The 2014-10-21 07:32:50 | 
 
 
Source: health 

Beijing university of Chinese medicine Deng Yong Guo-jian he 

        Recently, the national health and family planning commission and other departments issued "completes the commonly used low drug supply security work opinion" stipulated, directory of drugs for into the state's low-cost drugs, cancel the highest retail price for each specific variety, allow production operators within the average daily expenses standard, according to the drug production cost and market supply and demand to fix or adjust the retail price, to ensure the reasonable profit. 
 
        Policy was issued in one piece. However, in the implementation of a few months didn't get obvious effect, the industry worry that cheap medicine policy will into the dilemma of failed to sell. 
 
        The truth of the low-cost medicine to disappear 
 
        Cheap medicine situation can be summarized as: on the one hand is disappearing or are in short supply, most cheap medicine laissez faire, and disappearing at the rate of dozens of each year. Protamine is a cheap but irreplaceable heart surgery essential drugs, it break for almost let the national each big hospital in the stagnation of heart surgery. Chloramphenicol eye drops, three porn, compound liquorice tablets, cheap drugs such as fructus forsythiae solution poison pill also often appear shortage phenomenon. On the other hand, because of the low price low profits, drug companies often take "adopt a new bottle" simple method. After joining irrelevant components become a new drug, drug price immediately expanded several times, back to the market. 
 
        Investigate its reason, low medicine appeared above is the reason for difficulties in three points: 
 
        Drug pricing mechanism is not scientific commodity prices is composed of two elements, the production cost and profit. The production cost of goods, including the production of goods consumed raw materials, energy, equipment depreciation and Labour costs, etc.; Profit is to create value for society laborers currency performance. In the process of older drugs production, due to the rising value of their labor and the change of the currency, the price of older drugs should also change with the market to make corresponding adjustment. And our current pricing mechanism for "new the price, old medicine price", that is to say our country allow drug companies have an independent pricing power, have new drugs for older drugs with reference to previous prices by the government pricing. The government's price of older drugs almost not be promoted, and the squeeze on prices in the tender drug producers' profits space narrowing tends to be no. In this case, the manufacturer will reduce or even stop low profit pharmaceutical producing at a lower price, or "old wine in new bottles", to the new packaging of older drugs, change the name, and declare in the name of the new drugs, the price can be improved. 
 
        In addition, in the opinion, canceled, the highest price of drug sales only chemical medicine expenses within 3 yuan, traditional Chinese medicine (TCM) within 5 yuan. The price is low compared with other similar imported drugs, so while also can arouse the enthusiasm of drug firms production to some extent, but only from the production still cannot solve the plight of cheap medicine. Pharmaceutical production and circulation, there is a long chain, only the source of production was useless, if the drug companies are reluctant to agent, pharmacies are reluctant to replenish onr's stock, doctors are reluctant to prescribe medicine, these cheap medicine also can't into the hands of the patients. 
 
        New drug approval system loophole For a long time, the agency of "new drug" concept is not clear, with wider range of application for "new drug". "Drug registration management approach" article 12 of "new drug applications," describes as "not on sale in the territory of China drug registration", "to the listed pharmaceutical dosage forms change, the change method, adding new indications of drug registration according to the new drug application program to declare", "already approved of the existing national standards" and "biological products according to the new drug application program to declare", etc. This gives "in not in wine" older drugs provided an opportunity, more than a medicine. The access to new drug approval system also stipulates: "congruent varieties, but under the condition of the same quality, to replace the varieties with high price low prices." The agency, apparently, it was for examination and approval of new medicines for relatively loose, or rules of flaws, make the "new drug application process of generics" through examining and approving new drugs become older drugs "" a high price. 
 
        Take medicine medical system In medicine cure is to point to the doctor in the process of treating according to the prescribed medicine to receive their own income. Is more expensive, the medicine prescribed can have higher income, and general medicine won't have too big wave number, so the doctor is in favor of high drug price, which not only lead to cheap medicine producers in embarrassment, also makes the low medicine nature will gradually disappear in the market. 
 
        Comprehensive reform to make policy 
 
        Such analysis can see, solve the problem of shortage of cheap drugs and low profit, just cancel the purchase as simple and direct netting the highest price, and should be from drug approval, production, circulation, use for reform of the whole industrial chain. That is why cheap medicine policy "thunder, little rain". How can you cure? 
 
        For older drugs from on the price regulation, reasonable pricing government should implement pricing when adjusting drug prices into the open, in the process of the specification, which is the basis of the drug price management in basic data, technical standards, such as information public, at the same time invited representatives to hear different views, including authority certified public accountants and other professional social intermediary agencies, to the price to declare material review, implementation not only ensure low-cost medicine manufacturers, reasonable profit without drug prices artificially high. The main targets of drug prices is drug prices are high, and the range of the price is reasonable, protection enterprise engaged in new drug research and development. 
 
        New drug approval system should be regulated to strengthen the supervision for examination and approval of new drugs For new drug approval to loopholes, must first clear the concept of new drugs, or to narrow the scope of the new drug applications, should avoid the "generic", "transformed" older drugs with new drug. In this respect, can learn from the United States, namely the scope of new drugs, avoid "change packaging, specifications, dosage form" instead of "three medicines" turned into "innovation medicine". Second, the government in the new drug approval should be carried out into the open, scientific, refining the approval process and clear responsibility, through strong regulation. 
 
        To supplement the medical policy have been phased out The government should increase investment in medicine and health, reduce hospital financial dependence on the drug addition, implements the medicine separation, establish a scientific compensation mechanism and personnel salary system to adapt to the industry characteristics, to return to the origin of cure, drug to cut off the interests between the hospital and drug chains, allowing doctors willing to use cheap drugs, increase low survival of older drugs market space. Older drugs with the market demand at a lower price, will naturally have a pharmaceutical production enterprise to production, so as to solve the plight of older drugs gradually disappear at a low price. 
 
        To sum up, promoting low-cost classic medicine is not only beneficial to the people, to reduce spending, can also help countries to reduce the medical burden, make as many people to enjoy the basic medical security, should be the support of a popular project. Therefore, solve the low the plight of older drugs gradually disappear from the market, priority, should be gradual reform health care system, the perfection of the mechanism of drug prices, break on the medicine medical system, medical separate, prompting cheap classic medicine to return to the market.
 
 
The original link: http://www.jkb.com.cn/news/depth/2014/1021/352952.html